United States Últimas notícias

Johnson & Johnson (NYSE:JNJ) is reportedly in discussions to sell its DePuy Synthes orthopedics business to Apollo Global Management for approximately $20 billion.

Canadian Prime Minister Mark Carney says he'd like to see the creation of a global technology stability board to oversee artificial intelligence. He speaks exclusively to Bloomberg's Brian Platt in Toronto.

Biofrontera (NASDAQ:BFRI) received U.S. FDA approval of a supplemental New Drug Application for its Ameluz 10% topical gel and BF-RhodoLED lamp to treat adult patients with superficial basal cell carcinoma.

707 Cayman Holdings (NASDAQ:JEM) announced it will not proceed with its previously proposed acquisition of Crucial Innovation following a board review.

Immersion Corporation (NASDAQ:IMMR) reported total revenues of $294.4 million for the first quarter of fiscal 2027, reversing a prior-year net loss.

Amgen (NASDAQ:AMGN) received U.S. FDA approval to update the prescribing information for IMDELLTRA, reducing the initial monitoring time to 6–8 hours.

Boeing (NYSE:BA) and American Airlines (NASDAQ:AAL) completed the first 737 MAX landing gear exchange on September 14, 2026.

Canaan (NASDAQ:CAN) released its August 2026 update, mining 44 Bitcoin and securing US$13.9 million from asset sales.

Etihad Airways Chief Executive Officer Antonoaldo Neves discusses fuel price hedging and the risks around the conflict in the Middle East. He also talks about a possible future IPO, saying the airline doesn't have any plans for that. "We can finance our expansion with our own cash flow generation," Neves says. He speaks with Bloomberg's Abeer Abu Omar.

US Energy Secretary Chris Wright says he expects Saudi Arabia's East-West Pipeline to the Red Sea to be up and running "very soon." Wight also discusses flows of crude oil and oil products through the Strait of Hormuz and the status of the US's strategic petroleum reserve on "Bloomberg Surveillance."

Pasithea Therapeutics (NASDAQ:KTTA) announced that it will present initial clinical data from Part A of its ongoing Phase 1/1b trial evaluating PAS-004 in adults with neurofibromatosis type 1 (NF1).

RF Industries (NASDAQ:RFIL) reported record third-quarter fiscal 2026 net sales of $23.96 million, representing a 21% year-over-year increase.